Treatment of progressive fibrosing interstitial lung diseases (PF-ILD), also known as progressive pulmonary fibrosis (PPF), including idiopathic pulmonary fibrosis (IPF)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D12975 Nerandomilast
DG02924 UGT substrate
D12975 Nerandomilast
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12975
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12975
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12975